The Effect of Anti-viral Drugs Used in Late Pregnancy in Mothers With Hepatitis B Virus Infection on Long-term Development of Children
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 400
- 主要终点
- The rate of abnormal development
研究概览
简要总结
Mother to child transmission(MTCT) is the main route of hepatitis B virus(HBV) transmission.High HBV DNA level of pregnant women is the main risk factor of MTCT. Many literatures demonstrate that using nucleoside (acid) analogs in late pregnancy can significantly reduce HBV DNA level and effectively blocking MTCT. Therefore, treatment guidelines of hepatitis B in Europe and the Asia Pacific region clearly pointed out: Nucleoside (acid) analogs can be used in pregnant women after 28 weeks of gestation for blocking MTCT in mothers with high HBV DNA level. At present, the drugs used in late pregnancy including lamivudine (LAM) ,telbivudine(LdT) and tenofovir(TDF).
The safety of nucleoside (acid) analogues used in late pregnancy on children is not clear.In most of the related researches,the observation termination was 7-12 months after birth, and most were concentrated on the blocking effect of MTCT.The long-term impact of Nucleoside (acid) analogues on children's development has not been reported in the literatures. The aim of this study is to make clear of the effect of nucleoside (acid) analogues used in late pregnancy on long-term impact of children's development.
The one year old children born in Beijing Ditan hospital and whose mothers had taken LAM,LdT or TDF during late pregnancy will be enrolled as study group, and eligible children whose mothers untreated will be enrolled as control group. The children's height, weight, nutritional status, developmental quotient and immune response to hepatitis B vaccine etc will be evaluated at baseline and at 3 years old. By comparing the children's development in different groups as well as in self-control of different ages, we will discuss the effect of Nucleoside (acid) analogues on children's long-term development.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 1 Year 至 3 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The one year old children whose mothers had taken Lamivudine,Telbivudine or Tenofovir in late pregnancy(28-30 weeks of gestation);
- •The one year old children whose mothers untreated in late pregnancy;
- •Children had completed standard hepatitis B vaccine and hepatitis B immune globulin combined active and passive prophylaxis;
- •HBV DNA level of the children's mothers were over 6.0 log10 IU/ml before 28 weeks of gestation.
排除标准
- •Children whose mothers over 35 years old at delivery;
- •The couple having family hereditary disease or abnormal malformation has been found at fetal screening before 28 weeks gestation;
- •History of amniocentesis during pregnancy;
- •Co-infection with either hepatitis C virus, hepatitis D virus, human immunodeficiency virus, syphilis, toxoplasmosis, rubella or cytomegalovirus.
- •Complications of pregnancy-induced hypertension, premature rupture of membranes, preterm birth, placenta previa or placental abruption; asphyxia at birth.
研究组 & 干预措施
group A
The one year old children born in Beijing Ditan hospital and whose mothers had taken Lamivudine in late pregnancy
干预措施: Lamivudine (Drug)
group B
The one year old children born in Beijing Ditan hospital and whose mothers had taken Telbivudine in late pregnancy
干预措施: Telbivudine (Drug)
group C
The one year old children born in Beijing Ditan hospital and whose mothers had taken Tenofovir in late pregnancy
干预措施: Tenofovir (Drug)
结局指标
主要结局
The rate of abnormal development
时间窗: 6 months
The children' development will be measured by Gesell Developmental Scales, including adaptability, mobility, fine motion skills, language ability and social skills.The children will be considered normal if the score is ≥86, score between 76-85 is suspicious, and score≤75 is abnormal.
次要结局
未报告次要终点
研究者
Wei Yi
Chief physician
Beijing Ditan Hospital